Open Access Research article

Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8

Junichi Aizawa, Kenshi Sakayama, Setsuya Kamei, Teruki Kidani, Haruyasu Yamamoto, Yoshiaki Norimatsu and Hiroshi Masuno*

BMC Cancer 2010, 10:51  doi:10.1186/1471-2407-10-51

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

to consider an even better study medication ?

k tseng   (2010-07-09 17:32)  private practice email

You have been innovative in showing a common medication has the prospect of reducing tumor size and metastasis.

Would it be even better to study a medication in the same group, and yet clinically have less side effects, eg. pioglitazone in the future?

A similar success will enhance the chance of an already useful medication.

Competing interests

None declared

top

Post a comment